New ADHD pill for kids shows promise in joint Japan-China trial
NCT ID NCT07086313
First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This study tests a new medication called EB-1020, taken once daily as a capsule, to see if it safely reduces ADHD symptoms in children and adolescents aged 6-17. About 315 participants will be randomly assigned to receive a low dose, high dose, or placebo for 6 weeks. The main goal is to measure changes in ADHD symptoms using a standard rating scale.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
Locations
-
Hokkaido University Hospital
RECRUITINGSapporo, Japan
Conditions
Explore the condition pages connected to this study.